US Patent

US9611267 — Substituted tricyclic compounds as FGFR inhibitors

Composition of Matter · Assigned to Incyte Corp · Expires 2035-01-30 · 9y remaining

Vulnerability score 4/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects tricyclic compounds that inhibit one or more FGFR enzymes and are useful in treating FGFR-associated diseases such as cancer.

USPTO Abstract

The present invention relates to tricyclic compounds, and pharmaceutical compositions of the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer.

Drugs covered by this patent

Patent Metadata

Patent number
US9611267
Jurisdiction
US
Classification
Composition of Matter
Expires
2035-01-30
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Incyte Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.